



Symposium: Update on Vulnerable Plaque

## **Long-Term Effect of BVS on Plaque Morphology**

E. Regar, A. Karanasos Thoraxcenter Erasmus Medical Center Rotterdam, NL

# **BVS ABSORB Clinical Trial Program Long-Term Follow-up ≥ 5 Years**



### COHORT A

First in Men, n=30

Single de-novo lesion

### OCT:

Single center,n=16

Academic analysis
Thoraxcenter

Ormiston et al. Lancet 2008 Serruys et al. Lancet 2010 Simsek et al. Eurointerv 2014 Karanasos et al JACC 2014

### COHORT B

First in Men, n=101

Single de novo-lesion

### OCT:

**Multi-center,n=55** 

Corelab analysis
Cardialysis

Serruys et al. TCT 2015

# **BVS ABSORB Clinical Trial Program Long-Term Follow-up ≥ 5 Years**



### COHORT A

First in Men, n=30

Single de-novo lesion

### OCT:

Single center,n=16

**Academic analysis Thoraxcenter** 

Ormiston et al. Lancet 2008 Serruys et al. Lancet 2010 Simsek et al. Eurointerv 2014 Karanasos et al JACC 2014

### COHORT B

First in Men, n=101

Single de nove

### OCT:

Corelab analy: Palpography **Cardialysis** 

**Imaging follow-up** 


QCA

**Echogenicity** 

Multi-center,n IVUS, IVUS-VH

ОСТ

**MSCT** 




Serruys et al. TCT 2015

### IVUS Echogenecity Can Visualize Depolymerization of PLLA




Erasmus MC

The echogenecity on IVUS allows us to follow the Depolymerization of PLLA scaffold (preclinical)




# **BVS ABSORB**OCT Can Visualize Biointegration of PLLA Scaffold





# **BVS ABSORB**OCT Can Visualize Biointegration of PLLA Scaffold








**Late Lumen Loss** 






**Effect on Plaque Morphology?** 







IVUS follow-up of the First-in-man trial (ABSORB B1/B2) over 5 years (B1: n=21, B2: n=30)




Vessel area & plaque area show biphasic change with

- Increase between 1st & 2nd year
- Significant plaque reduction between 2nd & 5th year accompanied by an adaptive & constrictive remodeling of the vessel area
  - Vessel area
  - Plaque area





OCT follow-up of the First-in-man trial (ABSORB B1/B2) over 5 years (B1: n=21, B2: n=30)



Mean and minimum scaffold area increased significantly in the first 3 years.

Thereafter struts are no longer discernible at 5 years.


Mean lumen area & minimal lumen area were stable from 1 year to 5 years.

Neointima between and on top of struts are no longer measurable at 5 years since the struts are not discernible on OCT at 5 years





OCT & IVUS follow-up of the First-in-man trial (ABSORB B1/B2) over 5 years (B1: n=21, B2: n=30)




Change in plaque morphology which makes the media visible at 5 years

## Effect on Plaque Morphology - More details?



## BVS 1.0 (ABSORB A)




### **Effect on Plaque Morphology – More details?**





## BVS 1.0 (ABSORB A)

## **Complete strut resorption &** Formation of a signal-rich layer












### **Effect on Plaque Morphology – More details?**



### **BVS 1.0** (ABSORB A)

# Complete strut resorption & Formation of a signal-rich layer



Effect on Plaque Morphology - More details?



BVS 1.0 (ABSORB A)

Complete strut resorption & Formation of a signal-rich layer

How can we characterize this signal-intense layer and the underlying plaque?

underlying plaque?

### **Effect on Plaque Morphology – More details?**



# **BVS 1.0** (ABSORB A) **OCT Attenuation Imaging**


Fibrous	low
Calcium	low
Necrotic core	HIGH
Macrophages	very HIGH

Relation between tissue type & attenuation coefficient

### **Effect on Plaque Morphology – More details?**



# **BVS 1.0** (ABSORB A) **OCT Attenuation Imaging**




T. Kameyama

### **Effect on Plaque Morphology – More details?**



# **BVS 1.0** (ABSORB A) **OCT Attenuation Imaging**



Lumen


Adventit<u>ia</u>

100µm intervals starting from lumen surface

**Effect on Plaque Morphology – More details?** 




# **BVS 1.0** (ABSORB A) **OCT Attenuation Imaging**



### **Effect on Plaque Morphology – More details?**




# **BVS 1.0** (ABSORB A) **OCT Attenuation Imaging**



**Effect on Plaque Morphology – More details?** 




# **BVS 1.0** (ABSORB A) **OCT Attenuation Imaging**



Asymptomatic, non-flow limiting rupture in 1/8 pts

**Effect on Plaque Morphology – More details?** 







Baseline 6 months 2 year

**Effect on Plaque Morphology – More details?** 








Baseline 6 months 2 years 5 year

Garcia Garcia HM et al. EuroIntervention 2013


**Effect on Plaque Morphology - More details?** 







### **Effect on Plaque Morphology – More details?**










6 years

# **BVS ABSORB Effect on Plaque Morphology**



### Plaque composition & architecture can be modified.



# **BVS ABSORB Effect on Plaque Morphology**



- Both studies, Absorb Cohort A and Cohort B, show favourable effects on plaque morphology at 5 year follow-up:
- Complete bioresorption of BVS, with the formation of neoplaque and a sealing layer, which shows homogenous, low attenuating appearence in the majority of patiens.
- Stable lumen area between 2 years and 5 years
- Reduction in plaque area and vessel area.
- These results need to be interpreted with caution in light of the small number of patients and simple lesions.
- The observation of asymptomatic plaque rupture warrants further attention.



# Thank you for your attention!

#### PhD Students

A. Karanasos

C. Simsek

N. van Ditzhuijsen

J. van der Sijde

#### Cardiology

J. Ligthart

K. Witberg

R.J. van Geuns

P. de Jaegere

N. van Mieghem

J.Daemen

R. Diletti

F. Zijlstra

### Cardiology

H. van Beusekom

# Hemodynamics Laboratory

J. Wentzel F. Gijsen

#### \_.Jengineering

G. van Soest

A.F.W. van der Steen

### Imaging Group

N. Bruining

K. Sihan